Article

Detection of tau-PET positivity in clinically diagnosed mild cognitive impairment with multidimensional features.

2022-11-16

Abstract excerpt

<h4>Background: </h4> and purpose: The way to evaluate brain tau pathology in vivo is tau positron emission tomography (tau-PET) or cerebrospinal fluid (CSF) analysis. In the clinically diagnosed mild cognitive impairment (MCI), a significant proportion of tau-PET are negative. Interest in less expensive and convenient ways to detect tau pathology in Alzheimer's disease has increased due to the high cost of tau-PE...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c967610f-4ccd-50b4-9a85-f6094e76fe22
DOI: 10.21203/rs.3.rs-2263382/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Detection of tau-PET positivity in clinically diagnosed mild cognitive impairment with multidimensional features.DOI 10.21203/rs.3.rs-2263382/v1Read

Promising clinical tools for specific Alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unitSemantic proximity Read

Predicting Amyloid Pathology in Mild Cognitive Impairment Using Radiomics Analysis of Magnetic Resonance ImagingSemantic proximity Read

Multimodal Imaging and Logistic Weighted Cognitive Scores for Classification of MCI, AD, and FTD SubtypesSemantic proximity Read

Evaluating Sensitivity, Specificity, and Optimal Cutoff Scores of the Montreal Cognitive Assessment Using U.S. National Alzheimer Coordinating Centre Uniform Data Set: A Retrospective Analysis of 16,309 ParticipantsSemantic proximity Read

Comprehensive evaluation of AT(N) imaging biomarkers for predicting cognitionSemantic proximity Read

Standardized Comparison of Clinical, Cognitive, Genetic, Neuroimaging, and Fluid Biomarkers for Predicting 24-Month Progression from Mild Cognitive Impairment to Alzheimer’s DiseaseSemantic proximity Read

A machine learning-based prediction of tau load and distribution in Alzheimer’s disease using plasma, MRI and clinical variablesSemantic proximity Read

Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s diseaseSemantic proximity Read

Medial temporal tau can be a predictor for amyloid-ß positivity in mild cognitive impairmentSemantic proximity Read

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measuresSemantic proximity Read

A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profilesSemantic proximity Read

Integrating Machine Learning Pipelines for Multimodal Biomarker Prediction in Alzheimer’s and Parkinson’s Disease: A Component of the Neurodiagnoses FrameworkSemantic proximity Read